Hepatitis/MASH

Top news of the day from across the health care landscape.

The FDA has approved Vemlidy (tenofovir alafenamide) from Gilead for the treatment of chronic hepatitis B infection with compensated liver disease.

Research evaluates sofosbuvir use in hepatitis C patients with a mental health disease.

Vietnam War veterans are more likely to contract hepatitis C virus than any other veterans, and 65-year-old Joe Benko was no exception to the statistic.

Tenofovir-alafenamide combination approved by the FDA for chronic hepatitis B infection.

A veteran of the Vietnam War recounts the challenges of treatment for hepatitis C virus.

After being denied bail, the Afghani refugee who donned the cover of National Geographic in the 1980s, was rushed to a local hospital in Pakistan.

Phase 2 studies of GS-4997 presented successful results in patients with non-alcoholic steatohepatitis.

HIV positive patients coinfected with hepatitis may face elevated cancer risk.

Vaccine candidates for hepatitis C virus have been notoriously unsuccessful in preventing the infection.

A new trial investigates the use of Lambda in patients with hepatitis D virus.

Parts of a protein used in some HCV vaccine candidates are far too flexible to be successful.

Tennessee pharmacist admits to falsifying prior authorizations, medical lab reports, and drug test results for at least 51 hepatitis C patients prescribed Sovaldi, Harvoni, Viekira Pak, and Daklinza.

A former Clinical Pharmacy Manager at a Walgreens specialty pharmacy pleaded guilty to health care fraud crimes committed between October 2014 and April 2016.

Researchers examine interventions that may improve adherence in chronic viral hepatitis care.

Top articles of the week from The American Journal of Pharmacy Benefits.

Obstacles exist in making testing and treatment for hepatitis C routine practice in prison.

An update of distribution and circulation of HCV genotypes could help reduce disease burden.

A diagnostic blood test could diagnose patients in early stages of non-alcoholic fatty liver disease.

Coinfection with HIV plus a hepatitis B, C, or both, adds to the risk of non-Hodgkins lymphoma.

Despite widespread criticism, the United States may be paying less for hepatitis c virus drugs than other developed countries.

Six-week direct-acting antiviral treatment regimen with Sovaldi and ribavirin produced sub-optimal results in newly infected hepatitis C patients.

ElastPQ technique can better detect liver fibrosis in patients with hepatitis C.

In case you missed it, here's the hottest news in pharmacy this week:

Study quantifies global body composition changes in patients with hepatitis C.